Posting this ...because it seems to have been published as a paper just recently (?)
https://journals.lww.com/aidsonline/Abstract/9000/Tesamorelin_Improves_Fat_Quality_Independent_of.96444.aspx but it also seems to have been published as a poster at CROI 2018 and I hadn't seen any of it.
https://www.croiconference.org/abstract/tesamorelin-improves-fat-quality-independent-changes-fat-quantity/ https://2jg4quetidw2blbbq2ixwziw-wpengine.netdna-ssl.com/wp-content/uploads/sites/2/posters/2018/1430_Lake_736.pdf To be honest I don't know the relevance of it but whenever I read about the broad impact Egrifta has on various aspects of metabolic syndrome, fat etc it gives me a lot more confidence about what it might achieve with NASH. It would be great if the company could tie all these different aspects of Egrifta's biology together and relate it to NASH. They don't really go deep into this (they don't go deep into very much). For example hypertrophic adipocytes look superficially a lot like ballooning hepatocytes. Is there some connection there?
As an aside, responder rate in lipo is 70%, responder rate in liver fat reduction was 60%. If that could somehow translate in biopsy response rates it would be one attractive feature of the drug. Lot of stretching there though.